An exceptional response to 177LuPSMA undermined by neuroendocrine transformation

An exceptional response to 177LuPSMA undermined by neuroendocrine transformation

Blog Article

Approximately 25% of patients who have undergone extensive systemic therapy for advanced STRATEGIC DIRECTIONS FOR THE MANAGEMENT OF EDUCATIONAL PROGRAMS IN THE UNIVERSITY metastatic castration-resistant prostate cancer (mCRPC) develop treatment associated neuroendocrine prostate cancer (NEPC).177Lu-prostate specific membrane antigen (-PSMA) is an emerging alternative therapy for mCRPC patients who have exhausted other systemic therapy options; however, cells with neuroendocrine differentiation Fake social media news and distorted campaign detection framework using sentiment analysis & machine learning do not express PSMA and are not affected by this treatment.This case highlights an exceptional response of skeletal metastases to 177LuPSMA that is undermined by neuroendocrine transformation in the liver.